Spectrum Pharmaceuticals (SPPI) Raises Buyback Plan to $100M
Spectrum Pharmaceuticals (Nasdaq: SPPI) announced that the Company’s Board of Directors has approved an increase in its stock repurchase program authorizing the repurchase of up to a total of $100 million of the Company's common stock. The Company was previously authorized to repurchase up to $25 million of its stock.
You May Also Be Interested In
- Spectrum Pharma (SPPI) Issues MARQIBO, FOLOTYN at ASH 2013
- Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN® and MARQIBO® Clinical Data Presented at the 55th Annual Meeting of the American Society of Hematology (ASH)
- MasterCard (MA) Approves $3.5B Buyback; Announces 10-for-1 Split, 83% Dividend Increase
Create E-mail Alert Related CategoriesStock Buybacks
Related EntitiesStock Buyback
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!